LNAI Lunai Bioworks Inc.
USHealthcareAs of 2026-07-10 12:27
Why LNAI matters now
Lunai Bioworks Inc. (LNAI) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.91 with +6.59% on the session and $13.2M in market capitalization; recent performance reads 1-month +89.00% and YTD -46.38%.
The latest financial table shown here is Q3 2025, with revenue of $20.9K, net income of $-2.6M, and EPS of $-0.80. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.7%.
The latest indexable market news headline is "LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS" from PRNewsWire.
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.24
P/S
818.36
EV/EBITDA
-0.12
DCF Value
$-10.59
FCF Yield
-30.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-360.7%
Operating Margin
-46992.0%
Net Margin
-612568.1%
ROE
892.5%
ROA
-1301.0%
ROIC
120.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $20.9K | $-2.6M | $-0.80 |
| Q2 2025 | $0.00 | $-1.8M | $-0.61 |
| Q1 2025 | $0.00 | $2.8M | $1.04 |
| Q4 2024 | $0.00 | $-126.7M | $-60.88 |
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.36
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."